Search

Your search keyword '"Tima Joensuu"' showing total 9 results
Start Over Author "Tima Joensuu" Publication Year Range Last 50 years

Refine your results

9 results on '"Tima Joensuu"'

1. Supplementary Table 3 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Akseli Hemminki, Vincenzo Cerullo, Tuomo Alanko, Tima Joensuu, Leena Laasonen, Kaarina P. L. Partanen, Satu Kauppinen, Aila Karioja-Kallio, Sirkka-Liisa Holm, Elina Haavisto, Minna Oksanen, Kalevi Kairemo, Ann M. Leen, Ulrike Gerdemann, Saila K. Pesonen, Anna Kanerva, Tuuli Ranki, Lotta Kangasniemi, Iulia Diaconu, and Sari Pesonen

Abstract

PDF file - 48K, Description of disease at the time of first treatment.

Published
2023

2. Supplementary Figure 4 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Akseli Hemminki, Vincenzo Cerullo, Tuomo Alanko, Tima Joensuu, Leena Laasonen, Kaarina P. L. Partanen, Satu Kauppinen, Aila Karioja-Kallio, Sirkka-Liisa Holm, Elina Haavisto, Minna Oksanen, Kalevi Kairemo, Ann M. Leen, Ulrike Gerdemann, Saila K. Pesonen, Anna Kanerva, Tuuli Ranki, Lotta Kangasniemi, Iulia Diaconu, and Sari Pesonen

Abstract

PDF file - 1MB, PBMCs of a healthy donor was stimulated with supernatant collected from virus (CGTG-401 or control virus not coding CD40L) infected A549 lung cancer cells and IL-8 production was assessed 12, 24, 48, and 72 h later with FACSArray. The increase demonstrated at later time points indicates biological activity of the virus produced CD40L.

Published
2023

3. Supplementary Figure 3 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Akseli Hemminki, Vincenzo Cerullo, Tuomo Alanko, Tima Joensuu, Leena Laasonen, Kaarina P. L. Partanen, Satu Kauppinen, Aila Karioja-Kallio, Sirkka-Liisa Holm, Elina Haavisto, Minna Oksanen, Kalevi Kairemo, Ann M. Leen, Ulrike Gerdemann, Saila K. Pesonen, Anna Kanerva, Tuuli Ranki, Lotta Kangasniemi, Iulia Diaconu, and Sari Pesonen

Abstract

PDF file - 1.1MB, (A) Patient serum samples were analyzed for Th1 induced cytokines interferon-� (IFN-�), tumor necrosis factor-� (TNF-�) and interleukin-2 (IL-2) and Th2 cytokines interleukin-4 (IL-4), interleukin-5 (IL-5) and Interleukin 10 (IL-10). The ratio between Th1 and Th2 type cytokines was assessed. Cytokines levels are reported relative to their baseline level, which was set as 1 and a ratio between Th1/Th2 was calculated for each time point. (B) Malignant ascites of patient R8 and pleural effusion of patient T181 were analyzed for Th1 induced cytokines IFN-� and IL-2, and for Th2 induced IL-10 before and after treatment.

Published
2023

4. Supplementary Figure 2 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Akseli Hemminki, Vincenzo Cerullo, Tuomo Alanko, Tima Joensuu, Leena Laasonen, Kaarina P. L. Partanen, Satu Kauppinen, Aila Karioja-Kallio, Sirkka-Liisa Holm, Elina Haavisto, Minna Oksanen, Kalevi Kairemo, Ann M. Leen, Ulrike Gerdemann, Saila K. Pesonen, Anna Kanerva, Tuuli Ranki, Lotta Kangasniemi, Iulia Diaconu, and Sari Pesonen

Abstract

PDF file - 1.2MB, Blood samples for all 9 patients were collected before (baseline) and at several time points after the treatment. Soluble CD40L (sCD40L) and RANTES concentrations in the serum were assessed. Data are presented as median � SD.

Published
2023

5. Supplementary Table 2 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Akseli Hemminki, Vincenzo Cerullo, Tuomo Alanko, Tima Joensuu, Leena Laasonen, Kaarina P. L. Partanen, Satu Kauppinen, Aila Karioja-Kallio, Sirkka-Liisa Holm, Elina Haavisto, Minna Oksanen, Kalevi Kairemo, Ann M. Leen, Ulrike Gerdemann, Saila K. Pesonen, Anna Kanerva, Tuuli Ranki, Lotta Kangasniemi, Iulia Diaconu, and Sari Pesonen

Abstract

PDF file - 64K, Adverse reactions. 9 patients total, 6 received concomitant low-lose cyclophosphamide 50 mg/d, 3 did not. Numbers of patients experiencing the reaction at any time during their treatment (including 28d follow-up) is shown. The data is shown for the two subgroups separately in parentheses (cyclophosphamide/none).

Published
2023

6. Supplementary Table 5 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Akseli Hemminki, Vincenzo Cerullo, Tuomo Alanko, Tima Joensuu, Leena Laasonen, Kaarina P. L. Partanen, Satu Kauppinen, Aila Karioja-Kallio, Sirkka-Liisa Holm, Elina Haavisto, Minna Oksanen, Kalevi Kairemo, Ann M. Leen, Ulrike Gerdemann, Saila K. Pesonen, Anna Kanerva, Tuuli Ranki, Lotta Kangasniemi, Iulia Diaconu, and Sari Pesonen

Abstract

PDF file - 41K, Response evaluation of injected and non-injected lesions.

Published
2023

7. Supplementary Table 1 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Akseli Hemminki, Vincenzo Cerullo, Tuomo Alanko, Tima Joensuu, Leena Laasonen, Kaarina P. L. Partanen, Satu Kauppinen, Aila Karioja-Kallio, Sirkka-Liisa Holm, Elina Haavisto, Minna Oksanen, Kalevi Kairemo, Ann M. Leen, Ulrike Gerdemann, Saila K. Pesonen, Anna Kanerva, Tuuli Ranki, Lotta Kangasniemi, Iulia Diaconu, and Sari Pesonen

Abstract

PDF file - 58K, Prior therapies.

Published
2023

8. Supplementary Figure 1 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Akseli Hemminki, Vincenzo Cerullo, Tuomo Alanko, Tima Joensuu, Leena Laasonen, Kaarina P. L. Partanen, Satu Kauppinen, Aila Karioja-Kallio, Sirkka-Liisa Holm, Elina Haavisto, Minna Oksanen, Kalevi Kairemo, Ann M. Leen, Ulrike Gerdemann, Saila K. Pesonen, Anna Kanerva, Tuuli Ranki, Lotta Kangasniemi, Iulia Diaconu, and Sari Pesonen

Abstract

PDF file - 2MB, Serum levels for (A) IL-6, (B) IL-8, (C) IL-10, (D) IL-12, (E) TNF-alpha, and (F) IFN-gamma was assessed before and after the treatment. Data are presented separately for patients receiving virus treatment with or without concomitant low dose cyclophosphamide (50 mg/d) and shown as median � SD. NA, sample not available.

Published
2023

9. Supplementary Table 4 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Author

Akseli Hemminki, Vincenzo Cerullo, Tuomo Alanko, Tima Joensuu, Leena Laasonen, Kaarina P. L. Partanen, Satu Kauppinen, Aila Karioja-Kallio, Sirkka-Liisa Holm, Elina Haavisto, Minna Oksanen, Kalevi Kairemo, Ann M. Leen, Ulrike Gerdemann, Saila K. Pesonen, Anna Kanerva, Tuuli Ranki, Lotta Kangasniemi, Iulia Diaconu, and Sari Pesonen

Abstract

PDF file - 69K, Description of historical controls (Pesonen et al. Gene Ther 2010;17:892-904) treated with unarmed oncolytic adenovirus Ad5/3-cox2L-D24.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results